Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy
Xin Zheng,1 Kun Qian2,3 1Department of Hepatopancreatobiliary Surgery, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People’s Hospital, Yichang, People’s Republic of China; 2Department of Radiology, Union Hospital, Tongji Medical College, Huaz...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-06-01
|
| Series: | Journal of Hepatocellular Carcinoma |
| Subjects: | |
| Online Access: | https://www.dovepress.com/hepatic-arterial-infusion-chemotherapy-combined-apatinibcamrelizumab-f-peer-reviewed-fulltext-article-JHC |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849417826469675008 |
|---|---|
| author | Zheng X Qian K |
| author_facet | Zheng X Qian K |
| author_sort | Zheng X |
| collection | DOAJ |
| description | Xin Zheng,1 Kun Qian2,3 1Department of Hepatopancreatobiliary Surgery, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People’s Hospital, Yichang, People’s Republic of China; 2Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China; 3Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, 430022, People’s Republic of ChinaCorrespondence: Kun Qian, Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China, Email kunchien@163.comBackground: This study aimed to assess the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with apatinib and camrelizumab in patients with recurrent hepatocellular carcinoma (HCC) following hepatectomy.Methods: From July 2020 to December 2024, consecutive medical records of recurrent HCC patients treated with HAIC plus apatinib/camrelizumab were retrospectively reviewed. Key outcomes, including overall survival (OS), progression-free survival (PFS), therapeutic response, and treatment-related complications, were evaluated.Results: The study was followed up until January 31, 2025, with a median follow-up duration of 11 months (range: 2– 26 months). Among the 110 eligible recurrent HCC patients (91 males and 19 females), 62 deaths were recorded. The objective response rate (ORR) was 31.8%, and the disease control rate (DCR) was 87.3%. The median OS was 14 months (95% CI: 12.9– 15.1 months), with multivariable analysis identifying vascular invasion as an independent prognostic factor for OS. The median PFS was 7 months (95% CI: 5.3– 8.7 months), and the platelet-to-lymphocyte ratio was found to be an independent prognostic factor for PFS. All adverse events were manageable, and no treatment-related deaths occurred.Conclusion: HAIC combined with apatinib/camrelizumab is effective and safe in the treatment of recurrent HCC after hepatectomy, which may be a promising treatment for recurrent HCC.Keywords: hepatic arterial infusion chemotherapy, apatinib, camrelizumab, hepatocellular carcinoma, recurrent |
| format | Article |
| id | doaj-art-2f1eb8c8a8914f2d899999101da8e7c1 |
| institution | Kabale University |
| issn | 2253-5969 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Hepatocellular Carcinoma |
| spelling | doaj-art-2f1eb8c8a8914f2d899999101da8e7c12025-08-20T03:32:37ZengDove Medical PressJournal of Hepatocellular Carcinoma2253-59692025-06-01Volume 12Issue 112051215103936Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After HepatectomyZheng X0Qian K1Hepatopancreatobilary SurgeryDepartment of Radiology, Union HospitalXin Zheng,1 Kun Qian2,3 1Department of Hepatopancreatobiliary Surgery, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People’s Hospital, Yichang, People’s Republic of China; 2Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China; 3Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, 430022, People’s Republic of ChinaCorrespondence: Kun Qian, Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China, Email kunchien@163.comBackground: This study aimed to assess the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with apatinib and camrelizumab in patients with recurrent hepatocellular carcinoma (HCC) following hepatectomy.Methods: From July 2020 to December 2024, consecutive medical records of recurrent HCC patients treated with HAIC plus apatinib/camrelizumab were retrospectively reviewed. Key outcomes, including overall survival (OS), progression-free survival (PFS), therapeutic response, and treatment-related complications, were evaluated.Results: The study was followed up until January 31, 2025, with a median follow-up duration of 11 months (range: 2– 26 months). Among the 110 eligible recurrent HCC patients (91 males and 19 females), 62 deaths were recorded. The objective response rate (ORR) was 31.8%, and the disease control rate (DCR) was 87.3%. The median OS was 14 months (95% CI: 12.9– 15.1 months), with multivariable analysis identifying vascular invasion as an independent prognostic factor for OS. The median PFS was 7 months (95% CI: 5.3– 8.7 months), and the platelet-to-lymphocyte ratio was found to be an independent prognostic factor for PFS. All adverse events were manageable, and no treatment-related deaths occurred.Conclusion: HAIC combined with apatinib/camrelizumab is effective and safe in the treatment of recurrent HCC after hepatectomy, which may be a promising treatment for recurrent HCC.Keywords: hepatic arterial infusion chemotherapy, apatinib, camrelizumab, hepatocellular carcinoma, recurrenthttps://www.dovepress.com/hepatic-arterial-infusion-chemotherapy-combined-apatinibcamrelizumab-f-peer-reviewed-fulltext-article-JHChepatic arterial infusion chemotherapyapatinibcamrelizumabhepatocellular carcinomarecurrent |
| spellingShingle | Zheng X Qian K Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy Journal of Hepatocellular Carcinoma hepatic arterial infusion chemotherapy apatinib camrelizumab hepatocellular carcinoma recurrent |
| title | Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy |
| title_full | Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy |
| title_fullStr | Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy |
| title_full_unstemmed | Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy |
| title_short | Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy |
| title_sort | hepatic arterial infusion chemotherapy combined apatinib camrelizumab for recurrent hepatocellular carcinoma after hepatectomy |
| topic | hepatic arterial infusion chemotherapy apatinib camrelizumab hepatocellular carcinoma recurrent |
| url | https://www.dovepress.com/hepatic-arterial-infusion-chemotherapy-combined-apatinibcamrelizumab-f-peer-reviewed-fulltext-article-JHC |
| work_keys_str_mv | AT zhengx hepaticarterialinfusionchemotherapycombinedapatinibcamrelizumabforrecurrenthepatocellularcarcinomaafterhepatectomy AT qiank hepaticarterialinfusionchemotherapycombinedapatinibcamrelizumabforrecurrenthepatocellularcarcinomaafterhepatectomy |